We found that compared with OCA, a widely evaluated farnesoid X-activated receptor agonist with anti-MASLD activity,23 oral NTP had similar levels of antisteatotic, anti-inflammatory, hepatoprotective, and antifibrotic effects in our mouse model of MASLD/MASH induced by HFD/HFGW feeding. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.